Piper Jaffray Companies Reiterates “Buy” Rating for Becton, Dickinson and Company (NYSE:BDX)

Piper Jaffray Companies restated their buy rating on shares of Becton, Dickinson and Company (NYSE:BDX) in a research report report published on Tuesday, September 12th. They currently have a $213.00 price target on the medical instruments supplier’s stock.

Several other research analysts have also weighed in on the company. BidaskClub upgraded Becton, Dickinson and from a hold rating to a buy rating in a research report on Monday, August 14th. Cowen and Company reiterated a buy rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a research report on Monday, August 14th. Barclays PLC restated an equal weight rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Stifel Nicolaus restated a buy rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Zacks Investment Research cut Becton, Dickinson and from a buy rating to a hold rating in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $198.69.

Shares of Becton, Dickinson and (NYSE:BDX) opened at 193.06 on Tuesday. Becton, Dickinson and has a one year low of $161.29 and a one year high of $206.63. The stock has a market cap of $43.93 billion, a price-to-earnings ratio of 55.91 and a beta of 1.06. The company has a 50-day moving average price of $199.01 and a 200 day moving average price of $191.58.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business’s revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.35 earnings per share. Equities research analysts expect that Becton, Dickinson and will post $9.46 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Piper Jaffray Companies Reiterates “Buy” Rating for Becton, Dickinson and Company (NYSE:BDX)” was originally published by BBNS and is the sole property of of BBNS. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/becton-dickinson-ands-bdx-buy-rating-reiterated-at-piper-jaffray-companies/1638397.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. Becton, Dickinson and’s payout ratio is 83.43%.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC grew its stake in shares of Becton, Dickinson and by 35.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after buying an additional 11,300 shares during the period. Bessemer Group Inc. grew its stake in shares of Becton, Dickinson and by 1.4% during the 2nd quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock valued at $190,827,000 after buying an additional 13,263 shares during the period. State of Alaska Department of Revenue grew its stake in shares of Becton, Dickinson and by 5.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock valued at $6,438,000 after buying an additional 1,819 shares during the period. Union Bankshares Corp grew its stake in shares of Becton, Dickinson and by 1.7% during the 2nd quarter. Union Bankshares Corp now owns 22,335 shares of the medical instruments supplier’s stock valued at $4,357,000 after buying an additional 381 shares during the period. Finally, Retirement Systems of Alabama grew its stake in shares of Becton, Dickinson and by 4.8% during the 2nd quarter. Retirement Systems of Alabama now owns 161,834 shares of the medical instruments supplier’s stock valued at $31,575,000 after buying an additional 7,358 shares during the period. 87.12% of the stock is owned by institutional investors.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with our FREE daily email newsletter.

 


Latest News

Bryce Harper Hoping to Return Monday from Knee Injury
Bryce Harper Hoping to Return Monday from Knee Injury
American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?


Leave a Reply

 
© 2006-2017 BBNS.